The Journal of Neuropsychiatry and Clinical Neurosciences
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
J Neuropsychiatry Clin Neurosci 18:547-549, November 2006
doi: 10.1176/appi.neuropsych.18.4.547
© 2006 American Neuropsychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Kim, E.
* Articles by Bijlani, M.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Kim, E.
* Articles by Bijlani, M.

Clinical and Research Reports

A Pilot Study of Quetiapine Treatment of Aggression Due to Traumatic Brain Injury

Edward Kim, M.D., M.B.A. and Mona Bijlani, M.D.

Received September 7, 2005; revised December 6, 2005; accepted December 30, 2005. Dr. Kim is Clinical Associate Professor of Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, and Associate Director of Neuroscience Medical Strategy, Bristol-Myers Squibb Company, Plainsboro, New Jersey. Dr. Bijlani is Assistant Professor of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey. Address correspondence to Dr. Kim, Associate Professor of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 671 Hoes Lane, Piscataway, NJ 08855-1392; edward.kim{at}bms.com (E-mail).

ABSTRACT

In a 6-week open-label, flexible dose pilot study of quetiapine for treatment of aggression secondary to traumatic brain injury (TBI), seven subjects who were at least 3-months post-injury were enrolled. The Overt Aggression Scale – Modified (OAS-M) and Clinical Global Impression (CGI) were primary outcome measures. Administration of quetiapine at doses of 25 to 300mg daily was efficacious and well-tolerated in reducing irritability and aggression resulting from TBI, with an associated improvement in cognitive functioning.







Get information about faster international access.

Privacy Policy

Copyright © 2006 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Neuropsychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org